Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.

PloS one - 1 Jan 2015

Crane Erin K, Kwan Suet-Yan, Izaguirre Daisy I, Tsang Yvonne T M, Mullany Lisa K, Zu Zhifei, Richards JoAnne S, Gershenson David M, Wong Kwong-Kwok

Abstract excerpt

Epithelial ovarian cancer is a diverse molecular and clinical disease, yet standard treatment is the same for all subtypes. TP53 mutations represent a node of divergence in epithelial ovarian cancer histologic subtypes and may represent a therapeutic opportunity in subtypes expressing wild type, including most low-grade ovarian serous carcinomas, ovarian clear cell carcinomas and ovarian endometrioid carcinomas,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Introns

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 26248031
DOI: 10.1371/journal.pone.0135101
PMCID: PMC4527847

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.PMID 26248031Read ↗

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Semantic proximity Read ↗

p53 as a target for the treatment of cancer.Semantic proximity Read ↗

MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.Semantic proximity Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Semantic proximity Read ↗

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cellsSemantic proximity Read ↗

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAILSemantic proximity Read ↗

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer CellsSemantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.Semantic proximity Read ↗

Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.Semantic proximity Read ↗

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.